KR102416971B1 - 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 - Google Patents

브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR102416971B1
KR102416971B1 KR1020187029381A KR20187029381A KR102416971B1 KR 102416971 B1 KR102416971 B1 KR 102416971B1 KR 1020187029381 A KR1020187029381 A KR 1020187029381A KR 20187029381 A KR20187029381 A KR 20187029381A KR 102416971 B1 KR102416971 B1 KR 102416971B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
nhc
nhnh
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187029381A
Other languages
English (en)
Korean (ko)
Other versions
KR20180133415A (ko
Inventor
리안 허드슨
안느-마리 보솔레이
리차드 에이. 밀러
에릭 버너
Original Assignee
엔젤 파마슈티칼 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔젤 파마슈티칼 컴퍼니, 리미티드 filed Critical 엔젤 파마슈티칼 컴퍼니, 리미티드
Publication of KR20180133415A publication Critical patent/KR20180133415A/ko
Application granted granted Critical
Publication of KR102416971B1 publication Critical patent/KR102416971B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020187029381A 2016-03-11 2017-03-10 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 Active KR102416971B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
KR20180133415A KR20180133415A (ko) 2018-12-14
KR102416971B1 true KR102416971B1 (ko) 2022-07-04

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029381A Active KR102416971B1 (ko) 2016-03-11 2017-03-10 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법

Country Status (13)

Country Link
US (2) US10870652B2 (enExample)
EP (1) EP3426637B1 (enExample)
JP (1) JP6972002B2 (enExample)
KR (1) KR102416971B1 (enExample)
CN (2) CN115746000A (enExample)
AU (1) AU2017230098B2 (enExample)
CA (1) CA3017567A1 (enExample)
ES (1) ES2912465T3 (enExample)
IL (1) IL261583A (enExample)
MX (1) MX388026B (enExample)
PL (1) PL3426637T3 (enExample)
WO (1) WO2017156495A1 (enExample)
ZA (1) ZA201805951B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017567A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
WO2018175512A1 (en) * 2017-03-22 2018-09-27 Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
AU2020281410A1 (en) * 2019-05-31 2021-10-07 Haisco Pharmaceuticals Pte. Ltd. BTK inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
JP7213604B2 (ja) * 2019-09-26 2023-01-27 ジャンボ ドラッグ バンク カンパニー リミテッド 選択的ｂｔｋキナーゼ阻害剤としてのピラゾロピリジン系化合物
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
WO2022253250A1 (zh) * 2021-06-01 2022-12-08 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
TW202321191A (zh) * 2021-07-29 2023-06-01 美商賽迪拉治療股份有限公司 Ｔｅａｄ抑制劑及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
WO2007070398A1 (en) 2005-12-13 2007-06-21 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
US20070213327A1 (en) 2006-02-14 2007-09-13 Collier Philip N Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
WO2011099764A2 (en) 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells
US20160000792A1 (en) 2008-07-16 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
JP5613671B2 (ja) 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
PH12014500122A1 (en) * 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9458162B2 (en) 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
EA201891626A1 (ru) * 2016-01-21 2019-04-30 Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. Ингибиторы тирозинкиназы брутона
CA3017567A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
WO2007070398A1 (en) 2005-12-13 2007-06-21 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
US20070213327A1 (en) 2006-02-14 2007-09-13 Collier Philip N Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
US20160000792A1 (en) 2008-07-16 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2011099764A2 (en) 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells

Also Published As

Publication number Publication date
CN115746000A (zh) 2023-03-07
PL3426637T3 (pl) 2022-05-30
WO2017156495A8 (en) 2018-09-27
AU2017230098A1 (en) 2018-09-20
EP3426637A1 (en) 2019-01-16
CA3017567A1 (en) 2017-09-14
ZA201805951B (en) 2020-12-23
AU2017230098B2 (en) 2021-03-25
ES2912465T3 (es) 2022-05-26
US10870652B2 (en) 2020-12-22
MX2018010971A (es) 2019-03-28
CN109071455B (zh) 2022-08-02
EP3426637B1 (en) 2022-02-09
EP3426637A4 (en) 2019-09-18
WO2017156495A1 (en) 2017-09-14
US11306099B1 (en) 2022-04-19
KR20180133415A (ko) 2018-12-14
MX388026B (es) 2025-03-19
JP6972002B2 (ja) 2021-11-24
CN109071455A (zh) 2018-12-21
NZ745927A (en) 2024-05-31
JP2019507793A (ja) 2019-03-22
IL261583A (en) 2018-10-31
US20190106423A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
KR102416971B1 (ko) 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
AU2020201380B2 (en) Methods for treating Huntington's disease
CN113286794B (zh) Kras突变蛋白抑制剂
KR102540515B1 (ko) 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법
AU2017258187B2 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
CA3214900A1 (en) Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
WO2017044889A1 (en) Lrh-1 modulators
MX2012009606A (es) Compuestos deuterados de pirrolo-pirimidina como inhibidores de cdk4/6.
CA2693915A1 (en) Pyrazolo[1,5-a]pyrimidine derivatives
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
AU2018351059A1 (en) Benzimidazole derivatives and their uses
CN108430978B (zh) 3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
US20250263366A2 (en) Caspase 6 inhibitors and uses thereof
WO2024184550A1 (en) Biarylamide derivatives and their use as pkmyt1 inhibitors
AU2016341884B2 (en) Piperazinyl norbenzomorphan compounds and methods for using the same
WO2024008097A1 (zh) 靶向降解cdk蛋白的化合物及其应用
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2025008526A1 (en) Compounds containing a dialkylaryl moiety and their use
HK40009984A (en) Erbb inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200309

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211012

Patent event code: PE09021S01D

PN2301 Change of applicant

Patent event date: 20211209

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220425

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220630

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250602

Start annual number: 4

End annual number: 4